Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Clinical Pharmacology
Published in: BMC Clinical Pharmacology 1/2011

Open Access 01-12-2011 | Research article

Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts

Authors: Alla Kushnir, Joaquim MB Pinheiro

Published in: BMC Clinical Pharmacology | Issue 1/2011

Login to get access

Abstract

Background

Ibuprofen treatment of patent ductus arteriosus (PDA) has been shown to be as effective as indomethacin in small randomized controlled trials, with possibly fewer adverse effects. However, adverse renal effects of ibuprofen have been noted in some trials and suspected in our practice.
The purpose of this study was to examine whether ibuprofen and indomethacin treatment of PDA have comparable effects on renal function as evidenced by urine output and serum creatinine.

Methods

Retrospective chart review of 350 patients. Serum creatinine and urine output were recorded prior to start of treatment, during each course and after the last course of treatment. Pre-treatment mean creatinine and urine output values were compared to treatment and post treatment means using 2-factor repeated measures ANOVA.

Results

165 patients were treated with indomethacin (2005-2006) and 185 received ibuprofen (2007-2008). There was no difference between treatment groups in demographics or baseline renal function. For both groups, the number of treatment courses was inversely correlated with birth weight and gestational age. Analysis of the first course including all patients, revealed significant increase in creatinine and decrease in urine output with both drugs, with a more pronounced effect of indomethacin on creatinine. In the subgroup of 219 patients who received only one treatment course, there was a significant increase in creatinine after indomethacin, but not after ibuprofen. In the 131 who received 2 or more courses, the decrease in urine output and increase in creatinine were not different between drugs. There were significant decreases in urine output observed in the second and third courses of ibuprofen treatment (both by 0.9 mL/kg/hr).

Conclusion

Both drugs have a similar short-term effect on renal function. Indomethacin had a more prominent initial effect, while ibuprofen decreased renal function during the second and third courses similarly to indomethacin. The changes in renal function seen with ibuprofen treatment should be considered in fluid and electrolyte management, especially if treatment beyond one course is required.
Appendix
Available only for authorised users
Literature
1.
Evans N, Kluckow M: Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed. 1996, 75 (3): F183-F186. 10.1136/fn.75.3.F183.CrossRefPubMedPubMedCentral
2.
Martin CG, Snider AR, Katz SM, Peabody JL, Brady JP: Abnormal cerebral blood flow patterns in preterm infants with a large patent ductus arteriosus. J Pediatr. 1982, 101 (4): 587-93. 10.1016/S0022-3476(82)80715-4.CrossRefPubMed
3.
Wong SN, Lo RN, Hui PW: Abnormal renal and splanchnic arterial Doppler pattern in premature babies with symptomatic patent ductus arteriosus. J Ultrasound Med. 1990, 9 (3): 125-30.PubMed
4.
Cotton RB, Stahlman MT, Kovar I, Catterton WZ: Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr. 1978, 92 (3): 467-73. 10.1016/S0022-3476(78)80451-X.CrossRefPubMed
5.
Van Overmeire B, Smets K, Lecoutere D, Van de Broek H, Weyler J, Degroote K, Langhendries JP: A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000, 343 (10): 674-81. 10.1056/NEJM200009073431001.CrossRefPubMed
6.
Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE: Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med. 1976, 295 (10): 526-9. 10.1056/NEJM197609022951003.CrossRefPubMed
7.
Heymann MA, Rudolph AM, Silverman NH: Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med. 1976, 295 (10): 530-3. 10.1056/NEJM197609022951004.CrossRefPubMed
8.
Betkerur MV, Yeh TF, Miller K, Glasser RJ, Pildes RS: Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics. 1981, 68 (1): 99-102.PubMed
9.
van Bel F, Guit GL, Schipper J, van de Bor M, Baan J: Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr. 1991, 118 (4 (Pt 1)): 621-6.CrossRefPubMed
10.
Edwards AD, Wyatt JS, Richardson C, Potter A, Cope M, Delpy DT, Reynolds EO: Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet. 1990, 335 (8704): 1491-5. 10.1016/0140-6736(90)93030-S.CrossRefPubMed
11.
Varvarigou A, Bardin CL, Beharry K, Chemtob S, Papageorgiou A, Aranda JV: Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA. 1996, 275 (7): 539-44. 10.1001/jama.275.7.539.CrossRefPubMed
12.
Romagnoli C, De Carolis MP, Papacci P, Polimeni V, Luciano R, Piersigilli F, Delogu AB, Tortorolo G: Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates. Clin Pharmacol Ther. 2000, 67 (6): 676-83. 10.1067/mcp.2000.107048.CrossRefPubMed
13.
Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF: Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr. 1999, 135 (6): 733-8. 10.1016/S0022-3476(99)70093-4.CrossRefPubMed
14.
Lago P, Bettiol T, Salvadori S, Pitassi I, Vianello A, Chiandetti L, Saia OS: Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr. 2002, 161 (4): 202-7. 10.1007/s00431-002-0915-y.CrossRefPubMed
15.
Mosca F, Bray M, Lattanzio M, Fumagalli M, Tosetto C: Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr. 1997, 131 (4): 549-54. 10.1016/S0022-3476(97)70060-X.CrossRefPubMed
16.
Su BH, Lin HC, Chiu HY, Hsieh HY, Chen HH, Tsai YC: Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2008, 93 (2): F94-F99.CrossRefPubMed
17.
Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, Brotherton T: Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978, 187 (1): 1-7. 10.1097/00000658-197801000-00001.CrossRefPubMedPubMedCentral
18.
Vermont Oxford Network Database: Manual of Operations. 2007, Burlington, VT: Vermont Oxford Network, Release 12.0
19.
International Committee for the Classification of Retinopathy of Prematurity: The International Classification of Retinopathy of Prematurity Revisited. 2005, 991-9. 123
20.
Papile LA, Burstein J, Burstein R, Koffler H: Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978, 92 (4): 529-34. 10.1016/S0022-3476(78)80282-0.CrossRefPubMed
21.
Clyman RI: Ibuprofen and patent ductus arteriosus. N Engl J Med. 2000, 343 (10): 728-30. 10.1056/NEJM200009073431009.CrossRefPubMed
22.
Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards AD: Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res. 2000, 47 (1): 36-42. 10.1203/00006450-200001000-00009.CrossRefPubMed
23.
Van Overmeire B, Follens I, Hartmann S, Creten WL, Van Acker KJ: Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonatal Ed. 1997, 76 (3): F179-F184. 10.1136/fn.76.3.F179.CrossRefPubMedPubMedCentral
24.
Tiker F, Yildirim SV: Acute renal impairment after oral ibuprofen for medical closure of patent ductus arteriosus. Indian Pediatr. 2007, 44 (1): 54-5.PubMed
25.
Vieux R, Desandes R, Boubred F, Semama D, Guillemin F, Buchweiller MC, Fresson J, Hascoet JM: Ibuprofen in very preterm infants impairs renal function for the first month of life. Pediatr Nephrol. 2010, 25 (2): 267-74. 10.1007/s00467-009-1349-9.CrossRefPubMed
26.
Gournay V, Roze JC, Kuster A, Daoud P, Cambonie G, Hascoet JM, Chamboux C, Blanc T, Fichtner C, Savagner C, Gouyon JB, Flurin V, Thiriez G: Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2004, 364 (9449): 1939-44. 10.1016/S0140-6736(04)17476-X.CrossRefPubMed
27.
Richards J, Johnson A, Fox G, Campbell M: A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics. 2009, 124 (2): e287-e293. 10.1542/peds.2008-2232.CrossRefPubMed
28.
Aranda JV, Clyman R, Cox B, Van Overmeire B, Wozniak P, Sosenko I, Carlo WA, Ward RM, Shalwitz R, Baggs G, Seth A, Darko L: A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants. Am J Perinatol. 2009, 26 (3): 235-45. 10.1055/s-0028-1103515.CrossRefPubMed
29.
Cotton RB, Stahlman MT, Bender HW, Graham TP, Catterton WZ, Kovar I: Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. J Pediatr. 1978, 93 (4): 647-51. 10.1016/S0022-3476(78)80910-X.CrossRefPubMed
30.
SUPPORT Study Group of the Eunice Kennedy Shriver NICHDNeonatal Research Network: Target Ranges of Oxygen Saturation in Extremely Preterm Infants. N Engl J Med. 2010, 362 (21): 1959-69.CrossRef
31.
Vermont Oxford Network: Vermont Oxford Network Database: 2009 Annual NICU Quality Management Report. 2010, Burlington, VT, Vermont Oxford Network
Metadata
Title
Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts
Authors
Alla Kushnir
Joaquim MB Pinheiro
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Clinical Pharmacology / Issue 1/2011
Electronic ISSN: 1472-6904
DOI
https://doi.org/10.1186/1472-6904-11-8

Other articles of this Issue 1/2011

BMC Clinical Pharmacology 1/2011 Go to the issue

Research article

No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study

Research article

Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study

Research article

Use, tolerability and compliance of spironolactone in the treatment of heart failure

Research article

Knowledge, attitudes and practice survey about antimicrobial resistance and prescribing among physicians in a hospital setting in Lima, Peru

Research article

What can we learn from consumer reports on psychiatric adverse drug reactions with antidepressant medication? Experiences from reports to a consumer association

Research article

Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer